Acadia Pharmaceuticals Inc (ACAD): Cost of Revenue
$89.00M
Year ended 2025-12-31
$100.98M
Trailing 12 months to 2026-06-30
+106.1%
3-year compound annual growth
| Period ended | Cost of Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $89.00M | +8.7% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $81.84M | +96.6% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $41.64M | +309.6% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $10.17M | -46.9% | 2025-02-27, From 2022-01-01 |
| 2021-12-31 | $19.14M | n/c | 2024-02-28, From 2021-01-01 |
| 2020-12-31 | $10.21M | -10.0% | 2023-02-28, From 2020-01-01 |
| 2019-12-31 | $11.34M | -8.3% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $12.38M | +36.4% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $9.08M | +195.2% | 2020-02-27, From 2017-01-01 |
| 2016-12-31 | $3.08M | n/a | 2018-02-27, From 2016-01-01 |
Cost of Revenue at similar companies
| Company | Year ended | Cost of Revenue | Change YoY |
|---|---|---|---|
| Acadia Pharmaceuticals Inc (ACAD) | 2025-12-31 | $89.00M | +8.7% |
| Prestige Consumer Healthcare Inc. (PBH) | 2026-03-31 | $493.13M | -2.0% |
| Madrigal Pharmaceuticals, Inc. (MDGL) | 2024-12-31 | $6.23M | n/a |
| Ionis Pharmaceuticals Inc (IONS) | 2025-12-31 | $15.91M | +41.9% |
| Indivior Pharmaceuticals, Inc. (INDV) | 2025-12-31 | $246.00M | +6.5% |
| Harmony Biosciences Holdings, Inc. (HRMY) | 2025-12-31 | $198.34M | +26.5% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $317.31M | +24.9% |
| Alkermes plc. (ALKS) | 2025-12-31 | $196.46M | -19.9% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $12.98M | +19.3% |
Compare ACAD, PBH, MDGL, IONS side by side · Screen every company in Pharmaceutical Preparations ↗